Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial

Biological Psychiatry

Volumn 44, Issue 2, 1998, Pages 77-87

  Rosenbaum, Jerrold F ^a   Fava, Maurizio ^a   Hoog, Sharon L ^b   Ascroft, Richard C ^b   Krebs, William B ^b  

^a Clinical Psychopharmacology Unit   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Discontinuation emergent events; Fluoxetine; Selective serotonin reuptake inhibitors; Treatment interruption; Withdrawal events

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGITATION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; WITHDRAWAL SYNDROME;

1-NAPHTHYLAMINE; ADULT; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HALF-LIFE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PLACEBOS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032527557     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00126-7     Document Type: Article

References (39)

1. Barr L.C., Goodman W.K., Price L.H. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry. 151:1994;289.
2. Bhaumik S., Wildgust H.J. Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders [letter]. Hum Psychopharmacol. 11:1996;337-338.
3. Buckalew L.W., Sallis R.E. Patient compliance and medication perception. J Clin Psychol. 42:1986;49-53.
4. Ceccherini-Nelli A., Bardellini L., Cur A., Guazzelli M., Maggini C., Dilsaver S.C. Antidepressant withdrawal Prospective findings [letter] . Am J Psychiatry. 150:1993;165.
5. Charney D.S., Heninger G.R., Sternberg D.E., Landis H. Abrupt discontinuation of tricyclic antidepressant drugs Evidence for noradrenergic hyperactivity . Br J Psychiatry. 141:1982;377-386.
6. Coupland N.J., Bell C.J., Potokar J.P. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 16:1996;356-362.
7. Demyttenaere K., Van Ganse E., Gregoire J., Gaens E., Masters P. Compliance in depressed patients treated with fluoxetine or amitriptyline. Int Clin Psychopharmacol. 13:1997;11-17.
8. Dilsaver S.C., Greden J.F. Antidepressant withdrawal phenomena. Biol Psychiatry. 19:1984;237-256.
9. Dilsaver S.C., Feinberg M., Greden J.F. Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry. 140:1983;249-251.
10. Dilsaver S.C., Greden J.J., Snider R.M. Antidepressant withdrawal syndromes Phenomenology and physiopathology . Int Clin Psychopharmacol. 2:1987;1-19.
11. Einbinder E. Fluoxetine withdrawal? [letter]. Am J Psychiatry. 152:1995;1235.
12. Fava G.A., Grandi S. Withdrawal syndromes after paroxetine and sertaline discontinuation [letter]. J Clin Psychopharmacol. 15:1995;374-375.
13. Frost L., Lal S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry. 152:1995;810.
14. Gillespie C, Wildgust HJ, Haddad P, Currie A (1996): SSRIs and withdrawal syndrome [abstract]. World Congress of Psychiatry, Madrid, August 23-28.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
16. Kasantikul D. Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thai. 78:1995;53-54.
17. Kellner R. A symptom questionnaire. J Clin Psychiatry. 48:1987;268-274.
18. Kellner R. The development of sensitive scales for research in therapeutics. Fava M., Rosenbaum J.F. Research Designs and Methods in Psychiatry. 1992;213-222 Elsevier, New York.
19. Keuthen N.J., Cyr P., Ricciardi J.A., Minichiello W.E., Buttolph M.L., Jenike M.A. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol. 14:1994;206-207.
20. Koopowitz L.F., Berk M. Paroxetine induced withdrawal effects. Hum Psychopharmacol. 10:1995;147-148.
21. Lazowick A.L., Levin G.M. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother. 29:1995;1284-1285.
22. Lejoyeux M, Adès J, Mourad I, Solomon J, Dilsaver S (1996): Antidepressant withdrawal syndrome: Recognition, prevention and management. CNS Drugs 278-292.
23. Leiter F.L., Nierenberg A.A., Sanders K.M., Stern T.A. Discontinuation reactions following sertraline. Biol Psychiatry. 38:1995;694-695.
24. Louie A.K., Lannon R.A., Ajari L.J. Withdrawal reaction after sertraline discontinuation [letter]. Am J Psychiatry. 151:1994;450-451.
25. Mallya G., White K., Gunderson C. Is there a serotonergic withdrawal syndrome? [letter]. Biol Psychiatry. 33:1993;851-852.
26. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
27. Montgomery S.A., Henry J., McDonald G., Dinan T., Lader M., Hindmarch I., et al. Selective serotonin reuptake inhibitors Meta-analysis of discontinuation rates . Int Clin Psychopharmacol. 9:1994;47-53.
28. Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegaard J., et al. Paroxetine in the treatment of panic disorder A randomised, double-blind, placebo-controlled study . Br J Psychiatry. 167:1995;374-379.
29. Olivier-Martin R. Facteurs psychologiques, observance et resistance aux traitements antidepresseurs (Psychological factors, compliance and resistance to antidepressant treatment) (abstract in English). Encephale. 12:1986;197-203.
30. Petersen R.C., Richelson E. Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells. Psychopharmacology (Berl). 76:1982;26-28.
31. Price J.S., Waller P.C., Wood S.M., Mackay A.V.P. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 42:1996;757-763.
32. Pyke R.E. Paroxetine withdrawal syndromes (letter). Am J Psychiatry. 152:1995;149-150.
33. Rothschild A.J. Selective serotonin reuptake inhibitor-induced sexual dysfunction Efficacy of a drug holiday . Am J Psychiatry. 152:1995;1514-1516.
34. Stoukides J.A., Stoukides C.A. Extrapyramidal symptoms upon discontinuation of fluoxetine (letter). Am J Psychiatry. 148:1991;1263.
35. Thompson D., Buesching D., Gregor K.J., Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Managed Care. 2:1996;1239-1246.
36. Tollefson G.D., Senogles S.E., Frey W.H. II, Tuason V.B., Nicol S.E. A comparison of peripheral and central human muscarinic receptor affinities for psychotropic drugs. Biol Psychiatry. 17:1982;555-567.
37. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 24:1993;203-220.
38. Young J.L., Zonana H.V., Shepler L. Medication noncompliance in schizophrenia Codification and update . Bull Am Acad Psychiatry Law. 14:1986;105-122.
39. Zajecka J., Fawcett J., Amsterdam J., Quitkin F., Reimherr F., Rosenbaum J., et al. Safety of abrupt discontinuation of fluoxetine A randomized, placebo-controlled study . J Clin Psychopharmacol. 18:1998;193-197.